Wall Street is firing on all cylinders this Thursday, with major upgrades hitting healthcare, telecom, and e-commerce while Treasury bond buybacks shake up yields and send gold surging past $4,500. Find out…
One large-cap drugmaker has quietly lapped its peers in 2026 without a single obesity drug in its lineup, while the companies chasing the hottest trend in pharma are fighting for second place…
Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.
Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two…
A single Phase 3 readout just shook the cancer treatment world, sending one biotech stock to its biggest single-day gain ever and forcing Wall Street to rethink whether personalized mRNA therapies have…
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math…
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even…
Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the…
Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about…
SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line…
A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
AbbVie's two newest drugs are growing so fast they've rewritten the company's entire story, and Wall Street may not have fully priced in what happens when the July 31 earnings report confirms…
Applying the Dogs of the Dow logic across the entire S&P 500 sounds like a recipe for chasing troubled dividends, but a holding-by-holding look at SDOG reveals a more complicated picture, with…
